NCT05621824Not yet recruiting
A Cohort Study on Screening and Follow-up of High-risk Population of PDAC Based on EUS
A Cohort Study on Screening and Follow-up of High-risk Population of Pancreatic Cancer Based on Endoscopic Ultrasonography
Source: ClinicalTrials.gov · Last updated 9 Apr 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Study objective: The purpose of this study is to establish a prospective follow-up cohort of high-risk groups of pancreatic cancer, screen early pancreatic cancer through EUS and other means according to the existing clinical process, and evaluate each risk factors. And to prospectively collect biological samples to find molecular markers for early diagnosis of pancreatic cancer. Study design: This is a real world, multicenter, prospective, observational cohort study.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 900 (estimated)
- First submitted
- 10 Nov 2022
- Start date
- Dec 2024
- Primary completion date
- Jun 2026
- Lead sponsor
- Peking Union Medical College Hospital
- Diseases
- Pancreatic cancer
- NCT number
- NCT05621824
What you commit to
- Study type: Observational
- Planned participants: 900
- From Dec 2024 to the primary completion date, Jun 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- B. The patient or family member could not understand the conditions and objectives of this study.
Lab values
- A. Those who are not suitable for endoscopic examination, including but not limited to: poor general condition, serious heart and lung disease, and difficult to tolerate the examination; coagulation disorders; platelets \<50 × 10\^9/L；those who are not suitable for endoscopic examination after interview by an endoscopic physician.
Who the study is looking for
- From the beginning of the study to the end of the study, the 18-80 year old patients who were admitted to Peking Union Medical College Hospital and related research centers and who met the high-risk population of pancreatic cancer understood and were willing to participate in the study and signed the informed consent form.
- In this study, the high-risk population of pancreatic cancer is defined as patients who meet any of the following conditions:
- A. Patients with previous history of pancreatitis (acute or chronic).
- B. Patients with pancreatic cancer related genetic background, including immediate relatives with a family history of pancreatic cancer. Or genetic syndrome related to pancreatic cancer. \[including hereditary breast cancer ovarian cancer syndrome (HBOCS), carney complex (CNC), familial adenomatous polyps (FAP), hereditary diffuse gastric cancer syndrome (HDGC), juvenile polyposis (JPS), cutaneous malignant melanoma (CMM), hereditary papillary renal cell carcinoma (HPRCC) and Lynch syndrome\]
- C. Patients with continuous or progressive increase of CA19-9 and CEA.
- D. Patients with potential malignant pancreatic tumors, including mucinous cystic tumor (MCN) and intraductal papillary myxoma of the pancreas (IPMN).
- E. Newly diagnosed patients with diabetes (within 3 years after diagnosis of diabetes).
- F. Other patients who are considered as having high risk factors for pancreatic cancer.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.